Next Article in Journal
High-Efficiency Oxygen Reduction to Hydrogen Peroxide Catalyzed by Oxidized Mo2TiC2 MXene
Previous Article in Journal
Heterogeneous Activation of Peroxymonosulfate by a Spinel CoAl2O4 Catalyst for the Degradation of Organic Pollutants
 
 
Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
Journals
Catalysts
Volume 12
Issue 8
10.3390/catal12080849
catalysts-logo
Submit to this Journal Review for this Journal Propose a Special Issue
► Article Menu

Article Menu

share Share announcement Help format_quote Cite question_answer Discuss in SciProfiles thumb_up
...
Endorse textsms
...
Comment
first_page
settings
Order Article Reprints
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Article

Stimulation of Akt Phosphorylation and Glucose Transport by Metalloporphyrins with Peroxynitrite Decomposition Catalytic Activity

by
Amanda M. Eccardt
1,2,
Ross J. Pelzel
1,3,
Thomas P. Bell
1,4 and
Jonathan S. Fisher
1,*
1
Department of Biology, Saint Louis University, St. Louis, MO 63103, USA
2
Pfizer Inc., Chesterfield, MO 63017, USA
3
Graduate Program in Neuroscience, University of Minnesota, Minneapolis, MN 55455, USA
4
School of Medicine, Saint Louis University, St. Louis, MO 63104, USA
*
Author to whom correspondence should be addressed.
Catalysts 2022, 12(8), 849; https://doi.org/10.3390/catal12080849
Submission received: 7 June 2022 / Revised: 18 July 2022 / Accepted: 26 July 2022 / Published: 2 August 2022
(This article belongs to the Section Biocatalysis)
Browse Figures
Versions Notes

Abstract

:
Iron porphyrin molecules such as hemin and iron(III) 4,4′,4″,4‴-(porphine-5,10,15,20-tetrayl)tetrakis(benzoic acid) (FeTBAP) have previously been shown to influence insulin signaling and glucose metabolism. We undertook this study to determine whether a catalytic action of iron porphyrin compounds would be related to their stimulation of insulin signaling and glucose uptake in C2C12 myotubes. FeTBAP did not display nitrite reductase activity or alter protein S-nitrosylation in myotubes, eliminating this as a candidate mode by which FeTBAP could act. FeTBAP displayed peroxynitrite decomposition catalytic activity in vitro. Additionally, in myotubes FeTBAP decreased protein nitration. The peroxynitrite decomposition catalyst Fe(III)5,10,15,20-tetrakis(4-sulfonatophenyl)porphyrinato chloride (FeTPPS) also decreased protein nitration in myotubes, but the iron porphyrin Fe(III)tetrakis(1-methyl-4-pyridyl)porphyrin pentachlorideporphyrin pentachloride (FeTMPyP) did not. FeTBAP and FeTPPS, but not FeTMPyP, showed in vitro peroxidase activity. Further, FeTBAP and FeTPPs, but not FeTMPyP, increased Akt phosphorylation and stimulated glucose uptake in myotubes. These findings suggest that iron porphyrin compounds with both peroxynitrite decomposition activity and peroxidase activity can stimulate insulin signaling and glucose transport in skeletal muscle cells.

1. Introduction

Biological and synthetically derived metalloporphyrins play roles in generation or scavenging of reactive nitrogen species (RNS). For example, it has been established that deoxymyoglobin has the ability to act as a nitrite reductase and thus catalyze the reduction of nitrite (NO2−) to form nitric oxide (NO) [1,2,3]. NO is a gaseous free radical that takes on a key role as a signaling molecule regulating physiological functions while also contributing to pathological progressions in skeletal muscle [4,5,6,7].
Peroxynitrite is a reactive nitrogen species (RNS) formed from the reaction between superoxide and nitric oxide [8]. Various iron-containing porphyrin compounds such as Fe(III)5,10,15,20-tetrakis(4-sulfonatophenyl)porphyrinato chloride (FeTPPS) and Fe(III)tetrakis(1-methyl-4-pyridyl)porphyrin pentachlorideporphyrin pentachloride (FeTMPyP) have been characterized as peroxynitrite decomposition catalysts due to their ability to catalytically scavenge peroxynitrite [9,10]. Peroxynitrite acts as a mediator of protein oxidation and nitration and can contribute to forms of metabolic dysfunction including insulin resistance [10,11,12].
Both NO and peroxynitrite have been shown to impair insulin signaling in skeletal muscle [4,5,12,13]. Nitric oxide increases S-nitrosylation of proteins due to its ability to react with cysteine residues [14,15]. This posttranslational modification prevents normal tyrosine phosphorylation of insulin receptor β with downstream suppression of phosphorylation of insulin receptor substrate 1 (IRS-1). Injection of mice with the peroxynitrite donor 3-morpholinosydnonimine (SIN-1) increased nitration of skeletal muscle IRS-1 and AKT [12]. This increase in nitrotyrosine was concomitant with decreased insulin signaling at the level of phosphatidylinositol 3-kinase activity and Akt phosphorylation [12].
We have recently shown that the metalloporphyrin iron(III) 4,4′,4″,4‴-(porphine-5,10,15,20-tetrayl)tetrakis(benzoic acid) (FeTBAP) could stimulate insulin signaling and glucose transport in skeletal muscle [16]. We attributed this to the peroxidase activity of FeTBAP. However, the stimulation of insulin signaling by FeTBAP occurred without a decrease in intracellular peroxide levels [16]. This suggests that some other action of FeTBAP mediates its effects on insulin signaling. Thus, we hypothesized that nitrite reductase or peroxynitrite decomposition activity of FeTBAP would be associated with the effects of FeTBAP on insulin signaling.
Here, we show that FeTBAP is a peroxynitrite decomposition catalyst and that it decreases protein nitration. We also show that FeTBAP and FeTPPS, which have both peroxidase and peroxynitrite decomposition activities, stimulate Akt phosphorylation and glucose transport in myotubes. These findings suggest potential roles of metallophorphryins with combined peroxidase and peroxynitrite decomposition activities in stimulation of insulin signaling and glucose uptake in skeletal muscle.

2. Results

2.1. FeTBAP Does Not Act as a Nitrite Reductase

Given the similarity in structure of FeTBAP to the heme group of myoglobin and the reports of the capabilities of deoxymyoglobin as a nitrite reductase [1,2,3], this study aimed at elucidating whether FeTBAP had similar function. Absorbance spectra monitoring the Soret band of FeTBAP illustrated a decrease in peak intensity after addition of reducing agents: dithionite, NADPH, or Trolox (Figure 1). Additionally, there was a further decrease in intensity of the Soret band upon the addition of nitrite (Figure 1). To corroborate these findings, S-nitrosylation was monitored in C2C12 myotubes. If FeTBAP acted as a nitrite reductase, this would result in nitric oxide production and thus an increase in S-nitrosylation [2,17,18]. However, after treatment with FeTBAP there was no difference in S-nitrosylation versus the control (data not shown). This suggests that under our conditions FeTBAP does not act as a nitrite reductase.

2.2. FeTBAP Acts as a Peroxynitrite Decomposition Catalyst

Next, we examined a role of FeTBAP in relation to peroxynitrite. Previous studies have shown that iron porphyrins such as FeTMPyP and FeTPPS act as peroxynitrite decomposition catalysts [9,10]. As shownin Figure 2A, incubation with peroxynitrite causes a shift and an increase in peak intensity of the FeTBAP Soret band. This spectral shift and increase in peak intensity is consistent with previous findings in studies of Fe-porphyrins as peroxynitrite decomposition catalysts [9]. Decomposition of peroxynitrite was then monitored at 302 nm. Peroxynitrite rapidly decomposed in the presence of FeTBAP (Figure 2B, * p < 0.05 versus (−) FeTBAP). Taken together, these data suggest that FeTBAP is a peroxynitrite decomposition catalyst.

2.3. FeTBAP Decreases Nitration of Tyrosine Residues

Previous studies have shown that peroxynitrite causes nitration of tyrosine residues on various proteins including IRS-1 and Akt [12]. This prevents tyrosine phosphorylation, resulting in inhibition of insulin-stimulated glucose uptake [12]. Having established that FeTBAP acts as a peroxynitrite decomposition catalyst, we asked whether FeTBAP would affect protein nitration levels. Treatment of C2C12 myotubes with FeTBAP for 18 h caused a decrease in nitrotyrosine levels on a prominent band at about 35 kDa (Figure 3A,B, * p < 0.05 versus control). FeTPPS caused a decrease in nitration at a prominent band at about 65 kDa (Figure 3C,D).

2.4. FeTBAP and FeTPPS Increase Akt Phosphorylation and Glucose Transport

Certain iron-containing porphyrins, such as FeTPPS, have been shown to rescue muscle cells from insulin resistance following treatment with peroxynitrite [12,13]. Further, we have recently reported that FeTBAP stimulates insulin signaling and glucose transport in skeletal muscle [16]. Thus, we asked whether Fe-porphyrin compounds, in general, have the ability to stimulate Akt phosphorylation and glucose transport. As shown in Figure 4A–C, treatment with FeTPPS or FeTBAP increased Akt phosphorylation in C2C12 myotubes (* p < 0.05 versus control). In contrast, FeTMPyP had no effect on Akt phosphorylation. We next determined whether the Fe-porphyrins would increase glucose uptake. Pretreatment with either FeTBAP or FeTPPS caused a significant increase in glucose transport (Figure 4D, * p < 0.01 versus basal control). However, pretreatment with FeTMPyP had no effect on glucose uptake.

2.5. FeTPPS and FeTBAP Act as Peroxidases

Given that FeTPPS and FeTMPyP have been characterized as peroxynitrite decomposition catalysts [9,10], we investigated whether these two porphyrins exhibited peroxidase activity as well. As shown in Figure 5, FeTBAP and FeTPPS both display peroxidase activity, while FeTMPyP does not.

3. Discussion

This study shows that FeTBAP has peroxynitrite scavenging abilities and decreases nitrotyrosine levels in skeletal muscle cells. Additionally, FeTPPS, a well-characterized peroxynitrite decomposition catalyst [9,19], increases insulin signaling and glucose transport in C2C12 myotubes and acts as a peroxidase. However, FeTMPyP, another well-characterized peroxynitrite decomposition catalyst [9,10], had no effect on Akt phosphorylation or glucose transport and did not exhibit peroxidase activity.
Due to its highly reactive nature, peroxynitrite contributes to disrupted cell signaling, apoptosis, and cell death [20]. Moreover, reactive nitrogen species have been implicated in various forms of pathophysiological complications and diseases including stroke, aging, cancer, and insulin resistance/diabetes [10,20]. Peroxynitrite leads to insulin resistance via the nitration of tyrosine residues on key proteins in the insulin-signaling pathway [12].
Previous work has demonstrated actions of peroxynitrite decomposition catalysts to rescue cells from insulin resistance [12,13,21]. Effects of these compounds are summarized in Table 1. Our data suggest that part of the mechanism of these compounds might be direct activation of insulin signaling and glucose transport as opposed to reversal of insulin resistance. In our previous work on FeTBAP, we found that its peroxidase activity protected skeletal muscle cells from peroxide-related insulin resisance [16]. However, FeTBAP also increased insulin signaling and glucose transport in cells that were not exposed to H2O2, even though FeTBAP did not decrease intracellular H2O2 in these cells. This suggests that some other property of FeTBAP contributes to stimulation of insulin signaling and glucose transport.
The heme breakdown product hemin has been investigated for its potential role in prevention of insulin resistance. For example, daily injections of hemin decreased whole-body glucose uptake during a hyperinsulinemic-euglycemic clamp for mice on a high fat diet [22]. Similarly, hemin injections twice a week for mice on a high fat diet decreased fasting and non-fasting plasma glucose concentrations toward the levels in chow-fed animals [23]. Likewise, hemin injections decreased fasting glucose and glucose area under the curve during an insulin tolerance test in fat-fed mice [24]. These improvements in glucoregulation were concomitant with increased insulin-stimulated phosphorylation of the insulin receptor and Akt in liver [24]. As reviewed by Schaer et al. [25], hemin regulates expression of antioxidant enzymes including heme oxygenase-1. Hemin also serves as a ligand for the nuclear receptor REV-ERB, which regulates expression of genes involved in processes including glucose metabolism [25]. Thus, hemin may act through changes in gene expression to influence glucoregulation. The current data demonstrate a role of iron porphoryins in acute regulation of insulin signaling and glucose uptake, suggesting that these compounds can act before any changes in gene expression would be realized.
Only a small number of proteins are nitrated, reflected in studies of the nitrated proteome that usually find 110 or fewer nitrated proteins [26]. A list of nitrated mouse proteins from DeepNitro [27,28], a curated database of tyrosine nitrated and S-nitrosylated sites, contains 120 proteins known to be nitrated (Table S1). None of the nitrated proteins with molecular weights approximating the molecular weights of the prominent nitrated protein bands in the current study appear to have overt roles in insulin signaling. It is possible that these bands serve of markers of overall nitration, and other nitrated proteins with roles in insulin signaling are under the threshold for detection. Future work should focus on identification of roles of nitration in insulin signaling and action. A focus in future investigation might be on proteins that can be nitrated or phosphorylated on the same tyrosine site. Nitration prevents phosphorylation of the hydroxyl group on a tyrosine [29]. Likewise, tyrosine phosphorylation impedes nitration of that tyrosine residue [29]. Thus, it will be important to understand the competitive effects of tyrosine nitration and phosphorylation in insulin signaling. Overall, our data suggest that compounds that possess both peroxidase and peroxynitrite decomposition activity are able to stimulate Akt phosphorylation and glucose transport in skeletal muscle cells. This suggests that in addition to protective effects against RNS and H2O2, these compounds can directly improve insulin signaling and glucose transport into skeletal muscle cells.

4. Materials and Methods

4.1. Materials

Phosphate buffered saline (PBS), trypsin-EDTA, penicillin-streptomycin, and Dulbecco’s modified Eagle’s medium (DMEM), 4,4′,4″,4‴-(porphine-5,10,15,20-tetrayl)tetrakis(benzoic acid) (TBAP), iron (II) sulfate heptahydrate, Chelex-100, (+)-6-Hydroxy-2,5,7,8-tetramethyl-chromane-2-carboxylic acid (Trolox), sodium nitrite, sodium hydrosulfite (dithionite), peroxynitrite, and primary antibody against 3-nitrotyrosine (Sigma-Aldrich Cat N5538, RRID:AB1840351, St. Louis, MO, USA) were purchased from Sigma Aldrich (St. Louis, MO, USA). Primary antibodies against phosphorylated-Akt (Ser473: Cell Signaling Technology Cat 9271, RRID:AB329825, Danvers, MA, USA), phosphorylated-Akt (Thr308: Cell Signaling Technology Cat 9275, RRID:AB329828), and pan Akt (Cell Signaling Technology Cat 9272, RRID:AB329827) were purchased from Cell Signaling Technologies (Danvers, MA, USA). S-nitrosocysteine primary antibody (Abcam Cat ab94930, RRID:AB10697568, Cambridge, MA, USA) was acquired from Abcam (Cambridge, MA, USA). D-glucose, sodium hydroxide, Pierce BCA protein assay kit, the secondary antibody goat anti-mouse conjugated to HRP, and the secondary antibody goat anti-rabbit conjugated to HRP were acquired from ThermoFisher Scientific (Rockford, IL, USA). FetalPlex was obtained from Gemini Bio-Products (Woodland, CA, USA). Horse serum was procured from Gibco Technologies (Gaithersburg, MD, USA). 4–20% SDS-PAGE gels were purchased from Expedeon (San Diego, CA, USA). Western Lighting Plus enhanced chemiluminescence reagent was obtained from Perkin Elmer (Hopkinton, MA, USA). Blotting Grade Blocker was procured from Bio-Rad Laboratories (Des Plaines, IL, USA). NADPH was purchased from Enzo (Farmingdale, NY, USA). Fe(III)5,10,15,20-tetrakis(4-sulfonatophenyl)porphyrinato chloride (FeTPPS) and Fe(III)tetrakis(1-methyl-4-pyridyl)porphyrin pentachlorideporphyrin pentachloride (FeTMPyP) were purchased from Cayman Chemical (Ann Arbor, MI, USA). FeTBAP was prepared as previously described [16]. Structures of the metalloporphyrins are shown in Figure 6.

4.2. Potential Role of FeTBAP as a Nitrite Reductase

In order to determine a possible role of FeTBAP as a nitrite reductase, the Soret band of 20 μM FeTBAP was monitored around 412 nm utilizing a UV-2501PC UV-Vis spectrophotometer purchased from Shimadzu Scientific (Columbia, MD, USA). FeTBAP was then reduced with one of the following reducing agents: 100 μM dithionite, 100 μM NADPH, or 100 μM Trolox. The spectrum was taken monitoring the Soret band around 412 nm. After reduction of FeTBAP, 200 μM sodium nitrite was added to the cuvette and absorbance spectra taken around 412 nm in order to monitor the effect on the Soret band of FeTBAP.

4.3. Cell Culture

C2C12 myoblasts were obtained from the American Type Culture Collection (Manassas, VA, USA). Cells were cultured following standard procedures [33,34] in low-glucose Dulbecco’s Modified Eagle’s medium (DMEM) without phenol red supplemented with 10% (v/v) FetalPlex (Gemini Bio, Atlanta, GA, USA) and containing penicillin-streptomycin. Cells were incubated in 5% CO2 at 37 °C. Myoblasts were monitored and passaged every other day. Once cells reached about 70% confluence, myoblasts were differentiated into myotubes for two days in low glucose DMEM without phenol red containing 2% (v/v) horse serum and penicillin-streptomycin.

4.4. Effect of FeTBAP on S-Nitrosylation

To evaluate an effect of FeTBAP treatment on levels of S-nitrosylation, a spontaneous modification of cysteine side chains by NO, C2C12 myotubes of a 12-well plate were pretreated for 2 h with 150 μM FeTBAP in DMEM without phenol red. Following treatment with FeTBAP, samples were harvested in lysis buffer comprised of 50 mM HEPES pH 7.4, 150 mM NaCl, 10% (v/v) glycerol, 1.5 mM MgCl, 1 mM EDTA, 10 mM Na4O7P2, 100 mM NaF, 2 mM Na3VO4, 10 mg/mL leupeptin, 10 mg/mL aprotinin, 0.5 mg/mL pepstatin, and 1 mM phenylmethylsulfonyl fluoride. Whole cell homogenate protein content was quantified with a bicinchoninic acid (BCA) protein assay (Thermo Scientific Pierce BCA Protein Assay Kit). Western blot analysis was then performed for S-nitrosocysteine and GAPDH.

4.5. Western Blot Analysis

After samples were run on 4–20% gels, they were transferred to nitrocellulose membranes. Membranes were blocked in 5% (w/v) nonfat dry milk (Bio-Rad, Hercules, CA, USA) in TRIS-buffered saline (TBS) with 0.1% (v/v) Tween-20 (TBST) and then incubated with primary antibodies in 1% (w/v) nonfat dry milk. After washing with TBST, membranes were incubated with horseradish peroxidase-linked secondary antibodies. Membranes were washed with TBST and then TBS before incubation with Western Lightning Plus (PerkinElmer, Waltham, MA, USA) enhanced chemiluminescence reagent, followed by CCD imaging (iBright CL1000, ThermoFisher Scientific). The primary antibody against GAPDH (Cell Signaling Technology Cat 8884, RRID:AB11129865) was conjugated to horseradish peroxidase, so there was not a need for incubation with secondary antibodies.

4.6. Peroxynitrite Decomposition Activity

In order to determine a possible role of FeTBAP as a peroxynitrite decomposition catalyst, the Soret band of 20 μM FeTBAP was first monitored around 412 nm following similar studies [9]. After the spectrum of FeTBAP was obtained, 300 μM peroxynitrite was added to the 1 mL cuvette, and absorbance spectra were taken around 412 nm to monitor the effect on the Soret band of FeTBAP. The decomposition of peroxynitrite was then monitored at 302 nm. This involved a preliminary read of the absorbance of 20 μM FeTBAP at 302 nm. 300 μM peroxynitrite was then added to the 1 mL quartz cuvette, and absorbance was recorded every 10 s for 50 s at 302 nm with a Spectronic Genesys 5 (Fitchburg, WI, USA). Readings were done in 0.1 M NaOH, pH 12.4, to prevent spontaneous decomposition of peroxynitrite.

4.7. Nitrotyrosine Levels in C2C12 Myotubes

As our data indicated that FeTBAP can catalyze peroxynitrite decomposition, we then determined the effect of treatment with FeTBAP on nitrotyrosine levels in cultured muscle cells. C2C12 myotubes were treated for 18 h with 150 μM FeTBAP in low-glucose DMEM without phenol red. Myotubes were harvested in lysis buffer, and whole cell homogenate protein content was quantified via a BCA protein assay. Western blot analysis was then performed for 3-nitrotyrosine and GAPDH.

4.8. Insulin Signaling

We previously reported that FeTBAP stimulates insulin signaling and glucose transport in skeletal muscle [16]. To determine if, in general, all iron containing porphyrins increase insulin action by C2C12 myotubes, cells were pretreated with 150 μM FeTBAP, FeTPPS, or FeTMPyP for 2 h in DMEM without phenol red. Following pretreatment, myotubes were incubated for 20 min in the presence or absence of 10 nM insulin. Samples were then harvested in lysis buffer, and whole cell homogenate protein content was quantified. Western blot analysis was then performed for P-Akt (Ser473), P-Akt (Thr308), and total Akt.

4.9. Glucose Transport

2-DG transport assays were performed as previously described [16]. C2C12 myotubes in 24-well plates were serum starved for 3 h and pretreated for 2 h with 150 μM FeTPPS, FeTBAP, or FeTPMyP. Following pretreatment, samples were incubated in the presence or absence of 100 nM insulin. To correct for background, some wells of myotubes were incubated for 20 min in the presence of 10 μM cytochalasin B, which prevents glucose uptake via glucose transport (GLUT) proteins. All wells were then washed with HEPES-buffered saline (HBS) (20 mM HEPES sodium salt, 140 mM sodium chloride, 5 mM KCl, 2.5 mM MgSO4, 1 mM CaCl2). Myotubes were incubated for 10 min in transport medium (10 μM 2-deoxyglucose and 1 μCi/mL 3H-2-deoxyglucose tracer in HBS) in the presence or absence of 100 nM insulin, with background wells containing 10 µM cytochalasin B. Transport medium was removed, and cells were washed with cold 0.9% (w/v) NaCl. Samples then incubated while shaking in 0.2 N NaOH with 0.2% (w/v) SDS for 30 min. Ultima Gold scintillation fluid was added to aliquots of each sample, and vials were read on a Tri-Carb 3100 TR liquid scintillation counter (PerkinElmer, Waltham, MA, USA). Data were normalized to protein content of the samples.

4.10. Peroxidase Activity

Peroxidase activity of FeTBAP, FeTPPS, and FeTMPyP was monitored utilizing TMB. 150 μM FeTBAP, FeTPPS, and FeTMPyP were reacted with 150 μM hydrogen peroxide and 150 μM TMB in a 100 mM sodium phosphate buffer pH 7.4. Absorbance was monitored every minute for 10 min at 653 nm. Oxidation of TMB was quantified using the extinction coefficient: 39 mM−1cm−1 [35].

4.11. Statistics

Comparisons of two means were done with Student’s t tests. Time course data were analyzed with a repeated measures ANOVA followed by post hoc comparisons of the experimental group versus the control group for each time point. Multiple group comparisons were performed by ANOVA followed by Dunnett post hoc tests when there was a control group or LSD post hoc tests to compare all groups.

4.12. Nitrated Mouse Proteins

A list of known nitrated proteins was obtained from the DeepNitro [27,28] database of nitrated and S-nitrosylated proteins from humans, mice, yeast, Arabidopsis, and Drosophila. These 761 proteins were cross-referenced against the entire mouse UniProt database [36,37] to obtain a group of 120 mouse proteins known to be tyrosine-nitrated. Molecular weights for these proteins were obtained from UniProt.

Supplementary Materials

The following are available online at https://www.mdpi.com/article/10.3390/catal12080849/s1, Table S1: List of curated nitrated mouse proteins from DeepNitro database with molecular weights from UniProt database.

Author Contributions

Conceptualization, A.M.E., R.J.P. and J.S.F.; methodology, A.M.E., R.J.P., T.P.B. and J.S.F.; formal analysis, A.M.E., R.J.P., T.P.B. and J.S.F.; investigation, A.M.E., R.J.P., T.P.B. and J.S.F.; resources, J.S.F.; original draft preparation, A.M.E.; writing—review and editing, A.M.E., R.J.P., T.P.B. and J.S.F.; supervision, J.S.F.; project administration, J.S.F.; funding acquisition, J.S.F. All authors have read and agreed to the published version of the manuscript.

Funding

This research was funded by United States Public Health Service award [R15DK102122] from the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) to Jonathan Fisher. The manuscript content is solely the responsibility of the authors and does not necessarily represent the official views of the NIDDK or the National Institutes of Health.

Data Availability Statement

Data is contained within the article or Supplementary Material.

Acknowledgments

The authors would like to thank Cass Dedert for technical support.

Conflicts of Interest

Authors declare no conflict of interest. The funders had no role in the design of the study; in the collection, analyses, or interpretation of data; in the writing of the manuscript, or in the decision to publish the results.

References

  1. Gladwin, M.T.; Kim-Shapiro, D.B. The functional nitrite reductase activity of the heme-globins. Blood 2008, 112, 2636–2647. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  2. Shiva, S.; Huang, Z.; Grubina, R.; Sun, J.; Ringwood, L.; MacArthur, P.H.; Xu, X.; Murphy, E.; Darley-Usmar, V.; Gladwin, M.T. Deoxymyoglobin Is a Nitrite Reductase That Generates Nitric Oxide and Regulates Mitochondrial Respiration. Circ. Res. 2007, 100, 654–661. [Google Scholar] [CrossRef] [PubMed]
  3. Rassaf, T.; Flögel, U.; Drexhage, C.; Hendgen-Cotta, U.; Kelm, M.; Schrader, J. Nitrite Reductase Function of Deoxymyoglobin. Circ. Res. 2007, 100, 1749–1754. [Google Scholar] [CrossRef] [PubMed]
  4. Carvalho-Filho, M.A.; Ueno, M.; Hirabara, S.M.; Seabra, A.B.; Carvalheira, J.B.; de Oliveira, M.G.; Velloso, L.A.; Curi, R.; Saad, M.J. S-nitrosation of the insulin receptor, insulin receptor substrate 1, and protein kinase B/Akt: A novel mechanism of insulin resistance. Diabetes 2005, 54, 959–967. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  5. Badal, S.; Brown, P.D.; Ragoobirsingh, D. Nitric oxide agents impair insulin-mediated signal transduction in rat skeletal muscle. BMC Biochem. 2006, 7, 17. [Google Scholar] [CrossRef] [Green Version]
  6. Stamler, J.S.; Meissner, G. Physiology of nitric oxide in skeletal muscle. Physiol. Rev. 2001, 81, 209–237. [Google Scholar] [CrossRef]
  7. Lane, P.; Gross, S.S. Cell signaling by nitric oxide. Semin. Nephrol. 1999, 19, 215–229. [Google Scholar] [PubMed]
  8. Beckman, J.S.; Beckman, T.W.; Chen, J.; Marshall, P.A.; Freeman, B.A. Apparent hydroxyl radical production by peroxynitrite: Implications for endothelial injury from nitric oxide and superoxide. Proc. Natl. Acad. Sci. USA 1990, 87, 1620–1624. [Google Scholar] [CrossRef] [Green Version]
  9. Stern, M.K.; Jensen, M.P.; Kramer, K. Peroxynitrite Decomposition Catalysts. J. Am. Chem. Soc. 1996, 118, 8735–8736. [Google Scholar] [CrossRef]
  10. Salvemini, D.; Wang, Z.Q.; Stern, M.K.; Currie, M.G.; Misko, T.P. Peroxynitrite decomposition catalysts: Therapeutics for peroxynitrite-mediated pathology. Proc. Natl. Acad. Sci. USA 1998, 95, 2659–2663. [Google Scholar] [CrossRef] [Green Version]
  11. Radi, R. Oxygen radicals, nitric oxide, and peroxynitrite: Redox pathways in molecular medicine. Proc. Natl. Acad. Sci. USA 2018, 115, 5839. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  12. Zhou, J.; Huang, K. Peroxynitrite mediates muscle insulin resistance in mice via nitration of IRbeta/IRS-1 and Akt. Toxicol. Appl. Pharmacol. 2009, 241, 101–110. [Google Scholar] [CrossRef] [PubMed]
  13. Duplain, H.; Sartori, C.; Dessen, P.; Jayet, P.-Y.; Schwab, M.; Bloch, J.; Nicod, P.; Scherrer, U. Stimulation of peroxynitrite catalysis improves insulin sensitivity in high fat diet-fed mice. J. Physiol. 2008, 586, 4011–4016. [Google Scholar] [CrossRef] [PubMed]
  14. Stamler, J.S.; Singel, D.J.; Loscalzo, J. Biochemistry of nitric oxide and its redox-activated forms. Science 1992, 258, 1898–1902. [Google Scholar] [CrossRef]
  15. Stamler, J.S. Redox signaling: Nitrosylation and related target interactions of nitric oxide. Cell 1994, 78, 931–936. [Google Scholar] [CrossRef]
  16. Eccardt, A.M.; Pelzel, R.J.; Mattathil, L.; Moon, Y.A.; Mannino, M.H.; Janowiak, B.E.; Fisher, J.S. A peroxidase mimetic protects skeletal muscle cells from peroxide challenge and stimulates insulin signaling. Am. J. Physiol. Cell Physiol. 2020, 318, C1214–C1225. [Google Scholar] [CrossRef] [PubMed]
  17. Bryan, N.S.; Grisham, M.B. Methods to detect nitric oxide and its metabolites in biological samples. Free Radic. Biol. Med. 2007, 43, 645–657. [Google Scholar] [CrossRef] [Green Version]
  18. Hare, J.M.; Beigi, F.; Tziomalos, K. Chapter Twenty-One-Nitric Oxide and Cardiobiology-Methods for Intact Hearts and Isolated Myocytes. In Methods in Enzymology; Cadenas, E., Packer, L., Eds.; Academic Press: San Diego, CA, USA, 2008; Volume 441, pp. 369–392. [Google Scholar]
  19. Lauzier, B.; Sicard, P.; Bouchot, O.; Delemasure, S.; Moreau, D.; Vergely, C.; Rochette, L. A peroxynitrite decomposition catalyst: FeTPPS confers cardioprotection during reperfusion after cardioplegic arrest in a working isolated rat heart model. Fundam. Clin. Pharmacol. 2007, 21, 173–180. [Google Scholar] [CrossRef]
  20. Stadler, K. Peroxynitrite-driven mechanisms in diabetes and insulin resistance—The latest advances. Curr. Med. Chem. 2011, 18, 280–290. [Google Scholar] [CrossRef] [Green Version]
  21. Drel, V.R.; Pacher, P.; Vareniuk, I.; Pavlov, I.A.; Ilnytska, O.; Lyzogubov, V.V.; Bell, S.R.; Groves, J.T.; Obrosova, I.G. Evaluation of the peroxynitrite decomposition catalyst Fe(III) tetra-mesitylporphyrin octasulfonate on peripheral neuropathy in a mouse model of type 1 diabetes. Int. J. Mol. Med. 2007, 20, 783–792. [Google Scholar] [CrossRef] [Green Version]
  22. Ju, T.J.; Kwon, W.Y.; Kim, Y.W.; Kim, J.Y.; Kim, Y.D.; Lee, I.K.; Park, S.Y. Hemin improves insulin sensitivity in skeletal muscle in high fat-fed mice. J. Pharm. Sci. 2014, 126, 115–125. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  23. Szkudelski, T.; Dłużewicz, K.; Sadoch, J.; Szkudelska, K. Effects of the activation of heme oxygenase-1 on hormonal and metabolic changes in rats fed a high-fat diet. Biomed. Pharm. 2017, 87, 375–380. [Google Scholar] [CrossRef] [PubMed]
  24. Luan, Y.; Zhang, F.; Cheng, Y.; Liu, J.; Huang, R.; Yan, M.; Wang, Y.; He, Z.; Lai, H.; Wang, H.; et al. Hemin Improves Insulin Sensitivity and Lipid Metabolism in Cultured Hepatocytes and Mice Fed a High-Fat Diet. Nutrients 2017, 9, 805. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  25. Schaer, D.J.; Buehler, P.W.; Alayash, A.I.; Belcher, J.D.; Vercellotti, G.M. Hemolysis and free hemoglobin revisited: Exploring hemoglobin and hemin scavengers as a novel class of therapeutic proteins. Blood 2013, 121, 1276–1284. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  26. Batthyány, C.; Bartesaghi, S.; Mastrogiovanni, M.; Lima, A.; Demicheli, V.; Radi, R. Tyrosine-Nitrated Proteins: Proteomic and Bioanalytical Aspects. Antioxid. Redox Signal 2017, 26, 313–328. [Google Scholar] [CrossRef]
  27. DeepNitro. Available online: http://deepnitro.renlab.org/ (accessed on 15 July 2022).
  28. Xie, Y.; Luo, X.; Li, Y.; Chen, L.; Ma, W.; Huang, J.; Cui, J.; Zhao, Y.; Xue, Y.; Zuo, Z.; et al. DeepNitro: Prediction of Protein Nitration and Nitrosylation Sites by Deep Learning. Genom. Proteom. Bioinform. 2018, 16, 294–306. [Google Scholar] [CrossRef]
  29. Abello, N.; Kerstjens, H.A.; Postma, D.S.; Bischoff, R. Protein tyrosine nitration: Selectivity, physicochemical and biological consequences, denitration, and proteomics methods for the identification of tyrosine-nitrated proteins. J. Proteome Res. 2009, 8, 3222–3238. [Google Scholar] [CrossRef]
  30. National Library of Medicine (US). National Center for Biotechnology Information, PubChem Compound Summary for CID 6610341, Mntbap. Available online: https://pubchem.ncbi.nlm.nih.gov/compound/6610341#section=2D-Structure (accessed on 15 July 2022).
  31. National Library of Medicine (US). National Center for Biotechnology Information, PubChem Substance Record for SID 26758697. Available online: https://pubchem.ncbi.nlm.nih.gov/substance/26758697#section=2D-Structure (accessed on 15 July 2022).
  32. National Library of Medicine (US). National Center for Biotechnology Information, PubChem Compound Summary for CID 16760420, FeTMPyP. Available online: https://pubchem.ncbi.nlm.nih.gov/compound/16760420#section=2D-Structure (accessed on 15 July 2022).
  33. Andrisse, S.; Patel, G.D.; Chen, J.E.; Webber, A.M.; Spears, L.D.; Koehler, R.M.; Robinson-Hill, R.M.; Ching, J.K.; Jeong, I.; Fisher, J.S. ATM and GLUT1-S490 Phosphorylation Regulate GLUT1 Mediated Transport in Skeletal Muscle. PLoS ONE 2013, 8, e66027. [Google Scholar] [CrossRef] [Green Version]
  34. Eccardt, A.M.; Bell, T.P.; Mattathil, L.; Prasad, R.; Kelly, S.C.; Fisher, J.S. Trans-Plasma Membrane Electron Transport and Ascorbate Efflux by Skeletal Muscle. Antioxidants 2017, 6, 89. [Google Scholar] [CrossRef] [Green Version]
  35. Mirazizi, F.; Bahrami, A.; Haghbeen, K.; Shahbani Zahiri, H.; Bakavoli, M.; Legge, R.L. Rapid and direct spectrophotometric method for kinetics studies and routine assay of peroxidase based on aniline diazo substrates. J. Enzym. Inhib. Med. Chem. 2016, 31, 1162–1169. [Google Scholar] [CrossRef]
  36. UniProt: The universal protein knowledgebase in 2021. Nucleic Acids Res 2021, 49, D480–D489. [CrossRef] [PubMed]
  37. UniProt. Available online: https://www.uniprot.org/ (accessed on 15 July 2022).
Catalysts 12 00849 g001 550
Figure 1. Decreased Soret band absorbance upon reduction is not reversed by nitrite. Absorbance spectra were obtained for 20 µM FeTBAP (black), FeTBAP after addition of reducing compounds ((A). 100 µM dithionite, (B). 100 µM NADPH, (C). 100 µM Trolox; red), and after addition of 200 µM nitrite to reduced FeTBAP (blue).
Figure 1. Decreased Soret band absorbance upon reduction is not reversed by nitrite. Absorbance spectra were obtained for 20 µM FeTBAP (black), FeTBAP after addition of reducing compounds ((A). 100 µM dithionite, (B). 100 µM NADPH, (C). 100 µM Trolox; red), and after addition of 200 µM nitrite to reduced FeTBAP (blue).
Catalysts 12 00849 g001
Catalysts 12 00849 g002 550
Figure 2. FeTBAP acts as a peroxynitrite decomposition catalyst. (A) Absorbance spectra of 20 µM FeTBAP before (black curve) and after (red curve) the addition of 300 µM peroxynitrite. (B) Peroxynitrite composition monitored at 302 nm for 20 µM FeTBAP. * p < 0.05 versus control without FeTBAP, n = 3–4/group.
Figure 2. FeTBAP acts as a peroxynitrite decomposition catalyst. (A) Absorbance spectra of 20 µM FeTBAP before (black curve) and after (red curve) the addition of 300 µM peroxynitrite. (B) Peroxynitrite composition monitored at 302 nm for 20 µM FeTBAP. * p < 0.05 versus control without FeTBAP, n = 3–4/group.
Catalysts 12 00849 g002
Catalysts 12 00849 g003 550
Figure 3. FeTBAP and FeTPPS decrease nitrotyrosine levels in C2C12 myotubes. C2C12 myotubes were incubated in the absence or presence of 150 µM FeTBAP, FeTPPS, or FeTMPyP for 18 h. (A,B) Western blot and quantitation for 3-nitrotyrosine and glyceraldehyde phosphate dehydrogenase (GAPDH) after incubation with FeTBAP. (C–E) Western blot and quantitation for 3-nitrotyrosine and GAPDH after incubation with FeTBAP, FeTPPS, or FeTMPyP. * p < 0.05 vs. control.
Figure 3. FeTBAP and FeTPPS decrease nitrotyrosine levels in C2C12 myotubes. C2C12 myotubes were incubated in the absence or presence of 150 µM FeTBAP, FeTPPS, or FeTMPyP for 18 h. (A,B) Western blot and quantitation for 3-nitrotyrosine and glyceraldehyde phosphate dehydrogenase (GAPDH) after incubation with FeTBAP. (C–E) Western blot and quantitation for 3-nitrotyrosine and GAPDH after incubation with FeTBAP, FeTPPS, or FeTMPyP. * p < 0.05 vs. control.
Catalysts 12 00849 g003
Catalysts 12 00849 g004 550
Figure 4. FeTBAP and FeTPPS increase insulin signaling and glucose transport in C2C12 myotubes. C2C12 myotubes were incubated in the absence or presence of 150 µM FeTBAP, FeTPPS, or FeTMPyP for 2 h. (A–C) Western blot and quantitation for for P-Akt (S473), P-Akt (Thr308), and Akt. * p < 0.05, **** p < 0.0001 versus control. (D) C2C12 myotubes were serum starved and incubated in the presence or absence of 150 µM FeTBAP, FeTPPS, or FeTMPyP for 2 h followed by an incubation in the presence or absence of 100 nM insulin and assay of 2-deoxyglucose (2DG) uptake. * p < 0.05 versus basal control.
Figure 4. FeTBAP and FeTPPS increase insulin signaling and glucose transport in C2C12 myotubes. C2C12 myotubes were incubated in the absence or presence of 150 µM FeTBAP, FeTPPS, or FeTMPyP for 2 h. (A–C) Western blot and quantitation for for P-Akt (S473), P-Akt (Thr308), and Akt. * p < 0.05, **** p < 0.0001 versus control. (D) C2C12 myotubes were serum starved and incubated in the presence or absence of 150 µM FeTBAP, FeTPPS, or FeTMPyP for 2 h followed by an incubation in the presence or absence of 100 nM insulin and assay of 2-deoxyglucose (2DG) uptake. * p < 0.05 versus basal control.
Catalysts 12 00849 g004
Catalysts 12 00849 g005 550
Figure 5. FeTPPS and FeTBAP display peroxidase activity while FeTMPyP does not. Peroxidase activity was monitored via spectrophotometric peroxidase assays containing 150 μM TMB, 150 μM FeTPPS, FeTMPyP, FeTBAP, and 150 μM hydrogen peroxide. *** p < 0.001, **** p < 0.0001 for comparisons indicated.
Figure 5. FeTPPS and FeTBAP display peroxidase activity while FeTMPyP does not. Peroxidase activity was monitored via spectrophotometric peroxidase assays containing 150 μM TMB, 150 μM FeTPPS, FeTMPyP, FeTBAP, and 150 μM hydrogen peroxide. *** p < 0.001, **** p < 0.0001 for comparisons indicated.
Catalysts 12 00849 g005
Catalysts 12 00849 g006 550
Figure 6. Metalloporphyrin structures. (A). structure of MnTBAP [30]. The FeTBAP structure is the same except for iron in the spot occupied by manganese. (B). structure of FeTPPS [31]. (C). structure of FeTMPyP [32]. These structure images are reused without special permission needed, according to the PubChem citation guidelines on reusing the 2D or 3D structure image of a compound or substance record.
Figure 6. Metalloporphyrin structures. (A). structure of MnTBAP [30]. The FeTBAP structure is the same except for iron in the spot occupied by manganese. (B). structure of FeTPPS [31]. (C). structure of FeTMPyP [32]. These structure images are reused without special permission needed, according to the PubChem citation guidelines on reusing the 2D or 3D structure image of a compound or substance record.
Catalysts 12 00849 g006
Table
Table 1. Effects of Fe-porphyrin treatment in insulin resistant or diabetic mice.
Table 1. Effects of Fe-porphyrin treatment in insulin resistant or diabetic mice.
Fe-PorphyrinAuthor(s)ConditionsResults
FeTPPSZhou et al. [12]Insulin resistant high fat diet-fed (HFD) miceAdministration of FeTPPS improved muscle insulin signaling and whole body insulin sensitivity
FeTPPSDuplain et al. [13]Insulin resistant high fat diet-fed miceFeTPPS treatment restored insulin signaling and glucose uptake. Diminished HFD-induced insulin resistance in mice
FeTMPSDrel et al. [21]Streptozotocin induced type 1 diabetic miceAlleviated various symptoms associated with diabetic neuropathy including manifest motor and sensory nerve conduction velocity deficits
Publisher’s Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Share and Cite

MDPI and ACS Style

Eccardt, A.M.; Pelzel, R.J.; Bell, T.P.; Fisher, J.S. Stimulation of Akt Phosphorylation and Glucose Transport by Metalloporphyrins with Peroxynitrite Decomposition Catalytic Activity. Catalysts 2022, 12, 849. https://doi.org/10.3390/catal12080849

AMA Style

Eccardt AM, Pelzel RJ, Bell TP, Fisher JS. Stimulation of Akt Phosphorylation and Glucose Transport by Metalloporphyrins with Peroxynitrite Decomposition Catalytic Activity. Catalysts. 2022; 12(8):849. https://doi.org/10.3390/catal12080849

Chicago/Turabian Style

Eccardt, Amanda M., Ross J. Pelzel, Thomas P. Bell, and Jonathan S. Fisher. 2022. "Stimulation of Akt Phosphorylation and Glucose Transport by Metalloporphyrins with Peroxynitrite Decomposition Catalytic Activity" Catalysts 12, no. 8: 849. https://doi.org/10.3390/catal12080849

Note that from the first issue of 2016, this journal uses article numbers instead of page numbers. See further details here.

Article Metrics

Back to TopTop